Press Releases

ABT participated in a joint Capital Markets Day together with four other life science and biotech companies on 13 June 2013.

Den 11. juni 2013 ble det avhold ordinær generalforsamling i Aqua Bio Technology ASA hos Advokatfirmaet Selmer DA, Tjuvholmen allé 1, 0252 Oslo.

Good 1Q13 results and significant orders announced last week prompted to revise our 2013 sales estimate upwards. Our Buy recommendation is reiterated under a higher target price of NOK 27.00 per share.[more]

Aqua Bio Technology today announced that the Company has received two orders with a combined value of approx NOK 3.3 million for its lead ingredient, Aquabeautine XL™.[more]

Aqua Bio Technology ASA har fått to bestillinger på sitt hovedprodukt Aquabeautine XL™ med en samlet verdi på om lag 3,3 millioner kroner.[more]

ABT today announced its first quarter 2013 financial results. The Company continued its revenue build-up and posted an EBITDA of 3.9 million.[more]

ABT fortsatte sin inntektsvekst i første kvartal 2013 og fikk et EBITDA-resultat på 3,9 millioner kroner.[more]

Det innkalles med dette til ordinær generalforsamling i Aqua Bio Technology ASA den 11. juni 2013 kl. 11.00 i lokalene til Advokatfirmaet Selmer DA, Tjuvholmen Allé 1, 0252 Oslo.[more]

Aqua Bio Technology har offentliggjort årsrapporten for 2012.

Aqua Bio Technology reported its 4Q12 results on February 13th, which largely met our expectations.[more]

ABT today announced its 2012 financial results. The Company had its commercial breakthrough in 2012 and posted revenues of NOK 20.3 million for the year. ABT’s revenues the year before were NOK 0.5 million.[more]

Aqua Bio Technology ASA hadde sitt kommersielle gjennombrudd i 2012 og selskapet oppnådde en omsetning på 20,3 millioner kroner. ABTs omsetning året før var 0,5 millioner kroner.[more]

Aqua Bio Technology har ansatt Espen Kvale som ny Driftsdirektør/Chief Operating Officer(”COO”).[more]

Aqua Bio Technology has appointed Espen Kvale as new Chief Operating Officer (“COO”).[more]

See Aqua Bio Technology's financial calendar for 2013

Aqua Bio Technology’s 3Q12 results reported on November 27 met our projections. Expecting further growth, our Buy recommendation is reiterated under a new target price of NOK 26.00 per share.[more]

ABT today announced its third quarter 2012 financial results. The Company had its commercial breakthrough in the third quarter, when it also launched three new products.[more]

Aqua Bio Technology ASA hadde sitt kommersielle gjennombrudd i tredje kvartal, samtidig som selskapet lanserte tre nye produkter.[more]

Aqua Bio Technology will release its 3Q12 results on November 27th. Expecting the sales to pick up, we reiterate our Buy recommendation and the target price of NOK 29.00 per share.[more]

Det vises til børsmelding datert 25. oktober 2012, vedrørende utøvelse av opsjoner. Kapitalforhøyelsen etter opsjonsutøvelsen er nå registrert i Foretaksregisteret. [more]

I henhold til utøvelse av opsjoner under opsjonsavtale med tidligere styreleder Tor Arne Talseth, har styret i ABT besluttet kapitalforhøyelse i henhold til fullmakt.[more]

ABT holdt lunsjpresentasjon for analytikere og investorer 26. september 2012.

Recent positive news flow from Aqua Bio Technology includes yesterday’s message about a contract of at least USD 21m with Restorsea. [more]

ABT today announced that the Company has secured a contract representing revenues of more than USD 20 million over the next six years.[more]

ABT har inngått en salgskontrakt med en verdi på mer enn 120 millioner kroner over de neste seks årene.[more]

Aqua Bio Technology released its Q2 report this morning. Three new products should be launched already next month and revenue growth for the rest of 2012 is expected by the company. We keep confidence in our estimates and our Buy...[more]

ABT today announced its second quarter and first half 2012 financial results. While the Company posted a significant sales increase in the first quarter, revenues in the second quarter fell behind. The Company shows a good profit...[more]

ABT hadde mindre salg i andre kvartal 2012 enn i det foregående kvartalet. Selskapet viser imidlertid god lønnsomhet etter første halvår. Tre nye produkter vil bli lansert i neste måned, tidligere enn planlagt. [more]

Aqua Bio Technology will present its Q2 results on August 28. After a couple of significant partnership deals signed in Q1, we reiterate our 12-month Buy recommendation and the target price of NOK 19.00 per share.[more]

Kapitalforhøyelsen etter styrefullmakt ble registrert i Foretaksregisteret i dag, 5. juli 2012. [more]

Ordinær generalforsamling ble avholdt i ABT i dag, 14. juni 2012, fra kl 12:00.[more]

Styrets erklæring om fastsettelse av lønn og annen godtgjørelse til ledende ansatte til ordinær generalforsamling 2011.

Det innkalles med dette til ordinær generalforsamling i Aqua Bio Technology ASA den 14. juni 2012 kl. 11.00 i lokalene til Advokatfirmaet Selmer DA, Tjuvholmen Allé 1, 0252 Oslo.[more]

Aqua Bio Technology released its Q1 report this morning. Two major sales agreements were hallmark events in the last quarter. We keep confidence in our estimates and our Buy recommendation should be repeated; last target price...

Aqua Bio Technology ASA (Oslo Axess: ABT) today announced its first quarter 2012 financial results. Two contracts with US based customers provided a market breakthrough and boosted the Norwegian marine biotech company’s sales in...[more]

To kontrakter med amerikanske kosmetikkselskaper ga gjennombrudd for Aqua Bio Technology ASA i første kvartal. Selskapets omsetning økte sterkt i kvartalet, som ble det første i selskapets historie med overskudd.[more]

Aqua Bio Technology will present its Q1 results on May 23. After a couple of significant partnership deals signed in Q1, we reiterate our 12-month Buy recommendation and the target price of NOK 19.00 per share.

ABT har sikret seg fire nye kunder i Asia. Samtlige nye kunder har valgt ABTs hovedprodukt Aquabeautine XL ™ som en nøkkelingrediens i nye hudpleieprodukter.[more]

ABT today announced that the Company has secured four new customers in Asia. [more]

Styret i Aqua Bio Technology ASA har i dag lagt fram årsrapport for 2011.

Following the recent announcement of a second significant partnership deal, we reiterate our positive view towards the company and our Buy recommendation 12 months forward. Our target price is slightly upped to NOK 19.00 per...

Aqua Bio Technology ASA (Oslo Axess: ABT) today announced an important contract with a US based personal care company. The customer will use ABT’s lead product Aquabeautine XL® as a key ingredient in a new line of facial skincare...[more]

Aqua Bio Technology ASA (Oslo Axess: ABT) today announced an important contract with a US based personal care company. The customer will use ABT’s lead product Aquabeautine XL® as a key ingredient in a new line of facial skincare...[more]

Following Aqua Bio Technology’s Q4 report and the Amway deal announcement today, we do not see any significant changes in the investment case. [more]

ABT today announced a partnership with Amway, one of the world’s largest direct sellers, for the use of ABT’s lead ingredient Aquabeautine XL® in ARTISTRY® skincare products. ABT expects the agreement to provide revenues of at...[more]

ABT har inngått en partneravtale med Amway, en av verdens ledende aktører innen direktesalg. Amway skal benytte ABTs hovedprodukt Aquabeautine XL® i sine ARTISTRY® hudpleieprodukter. ABT regner med at avtalen vil gi et salg på...[more]

Aqua Bio Technology ASA la i fjerde kvartal 2011 grunnlaget for vekst i 2012. Selskapet har fått på plass et verdensomspennende nettverk av distributører og har sikret finansiering av satsingen i 2012.[more]

ABT succeeded in preparing a basis for 2012 growth during the fourth quarter of 2011. The Company now has a worldwide network of distributors in place and financing of 2012 initiatives has been secured.[more]

Encouraged by recent positive development in partnering activities, we reiterate our Buy recommendation under a higher target price of NOK 15.00 per share.

ABT is pleased to announce that Amway will exercise the option to use ABT’s lead ingredient Aquabeautine XL® in a new product line in its premium skincare brand ARTISTRY®.[more]